Abstract. Macrophages are active contributors to the innate immune defense system. As macrophage activation is clearly affected by the surrounding microenvironment, the present study investigated the effect of sulforaphane (SFN) on the bactericidal activity of macrophages and the underlying molecular mechanisms involved in this process. Human THP-1-derived macrophages, primary human peripheral blood mononuclear cell-derived macrophages, and primary mouse bone marrow derived-macrophages (BMDMs) pretreated with SFN or DMSO were utilized in a model of *Staphylococcus aureus* infection. The results suggested that SFN pretreatment of macrophages effectively repressed the intracellular survival of *S. aureus* through modulation of p38/JNK signaling and decreased *S. aureus*-induced caspases-3/7-dependent cell apoptosis, potentially through downregulation of microRNA (miR)-142-5p and miR-146a-5p. As SFN is a well-known activator of nuclear factor erythroid 2-related factor 2 (Nrf2), Nrf2-/- BMDMs were used to demonstrate that the SFN-mediated inhibitory effect was independent of Nrf2. Nevertheless, an increase in intracellular bacterial survival in Nrf2-deficient macrophages was observed. In addition, SFN pretreatment suppressed *S. aureus*-induced transcriptional expression of genes coding for the proinflammatory cytokines interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α), as well as for the M1 markers C-C motif chemokine receptor 7, IL-23 and inducible nitric oxide synthase (iNOS). Western blot analysis indicated that *S. aureus* challenge activated p38 mitogen-activated protein kinase (MAPK) (p38) and c-Jun N-terminal kinase (JNK) MAPK signaling pathways, while SFN pretreatment prevented p38 and JNK phosphorylation. Pretreatment with 2 specific inhibitors of p38 and JNK, SB203580 and SP600125, respectively, resulted in a decrease in *S. aureus*-induced proinflammatory gene expression levels compared with those observed in the SFN-pretreated macrophages. Furthermore, THP-1-derived macrophages pretreated with SB203580 or SP600125 prior to bacterial infection exhibited a significant inhibition in intracellular *S. aureus* survival. In conclusion, we hypothesize that concomitant targeting of the p38/JNK-inflammatory response and the *S. aureus*-induced apoptosis with SFN may be a promising therapeutic approach in *S. aureus* infection.

Introduction

During bacterial infection, the innate immune system triggers a rapid and non-specific inflammatory response mechanism to prevent the spread of bacteria. As one of the first defense mechanisms used, the phagocytic macrophages serve an important role in clearing foreign particles, including bacteria and cell debris, by phagocytosis and by restoring cell homeostasis to prevent tissue damage (1,2). Following microbial or cell debris recognition, the acute inflammatory response is initiated and triggers the rapid release of proinflammatory mediators such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α), which will subsequently induce the adaptive immune system (3,4). In addition to their phagocytic activity, macrophages serve an essential role in the maintenance of tissue homeostasis. Furthermore, they exhibit an uncommon plasticity and are able to polarize into subsets of proinflammatory or anti-inflammatory populations depending on their surrounding environment and their own phagocytic activity (5). The mitogen-activated protein kinase (MAPK) signaling pathways, which include the most studied members ERK, p38 MAPK (p38) and JNK, are instrumental in all
innate immune receptor signaling pathways. The MAPKs act by modulating the expression of inflammatory cytokines and chemokines (6,7).

*Staphylococcus aureus*, a gram-positive human bacterium, is a commensal opportunistic pathogen. It is a leading cause of skin and soft tissue infections, osteomyelitis, septic arthritis, pneumonia and endovascular infections (8). Unfortunately, treatments are complicated by the prevalence of multi-drug resistance strains, which result in high mortality and morbidity rates (9). Originally considered an extracellular pathogen, it has been demonstrated that *S. aureus* is also able to invade, survive and replicate within mammalian phagocytic and non-phagocytic cells using various survival strategies (10). A pathogenic characteristic of *S. aureus* is its ability to generate intense local and systemic inflammatory responses, evident in the release of inflammatory cytokines. Once released within the infected tissue environment, the cytokines act on the surrounding epithelial, stromal, and circulating cells, triggering secondary waves of cytokine release, consequently amplifying the host defense response. Uncontrolled levels of cytokines are detrimental to the host, resulting in massive tissue destruction.

Sulforaphane (SFN), a degradation product of glucosinolates, is an isothiocyanate derivative naturally present in cruciferous vegetables such as broccoli sprouts. SFN is a potent enhancer of phase II detoxification enzymes with antimicrobial activities against a variety of bacterial and fungal species (11-13). While several in vitro studies have described SFN antimicrobial activity, SFN treatment in *Helicobacter pylori* infection was the most studied. This pathogenic bacteria is involved in gastric epithelium infection and is associated with gastric cancer, and at present, the molecular mechanism involved in the bactericidal effect of SFN against *H. pylori* remains elusive (11,14). Recently, treatment with SFN was demonstrated to inhibit HIV infection in THP-1-derived macrophages and primary macrophages, but not primary T cells (15). In this case, the inhibitory effect of SFN on microbial persistence is exerted through a nuclear factor erythroid 2-related factor 2 (Nrf2)-dependent mechanism. SFN is a well-known activator of the transcription factor Nrf2, a key regulator of genes coding for phase II detoxifying enzymes, including NAD(P)H quinone dehydrogenase 1 (NQO1) and heme oxygenase-1 (HO-1), cytoprotective, antioxidant and anti-inflammatory responses (16,17). Nrf2 is an essential factor in the attenuation of inflammation since Nrf2-deficient mice exhibit increased inflammation (18). In addition, Nrf2 has been suggested to negatively regulate the transcription of IL-1β and IL-6 proinflammatory cytokine genes in lipopolysaccharide (LPS)-treated mouse bone marrow-derived macrophages (19).

Post-transcriptional regulation by microRNAs (miRNAs) has emerged as a major regulatory mechanism to control their expression (20). SFN and other glucosinolate derivatives have been demonstrated to modulate epigenetic alterations identified during carcinogenesis, including DNA methylation, histone modifications and miRNAs (22).

The present study investigated the underlying cellular mechanisms initiated by the pretreatment of human THP-1-derived macrophages, primary human peripheral blood mononuclear cells (PBMC)-derived macrophages, and primary mouse bone marrow-derived macrophages (BMDMs) with SFN and subsequent challenge with *S. aureus*. The effect of SFN pretreatment on the intracellular survival of *S. aureus*, macrophage apoptosis and macrophage inflammatory response was evaluated. Furthermore, Nrf2−/− BMDMs were used to assess whether the Nrf2 signaling was involved. Finally, the cellular signaling pathways, regulated by SFN and involved in the decrease in intracellular *S. aureus* survival, were examined using specific MAPK inhibitors. The results provided novel insights into the molecular mechanisms underlying the anti-inflammatory and anti-apoptotic activities mediated by SFN to disrupt *S. aureus*-favored environment in macrophages.

**Materials and methods**

**Antibodies and reagents.** SFN, phorbol 12-myristate 13-acetate (PMA), phallolidin-ATTO 594 (cat. no. 51927) were purchased from Sigma-Aldrich; Merck KGaA. The RPMI-1640 medium, heat-inactivated fetal bovine serum (FBS), FAM-FLICA caspases-3/7 assay kit (ImmunoChemistry Technologies, LLC) and human recombinant granulocyte-macrophage colony-stimulating factor (GM-CSF) were obtained from Eurobio Scientific. The Tryptic soy broth and Tryptic soy agar plates were purchased from Difco Becton Dickinson (Bd Biosciences). The iTaq SYBR-Green Supermix and dECREased S. aureus SURVIVAL IN SULFORAPHANE-TREATED MACROPHAGES
PBMcs were cultured in the abovementioned culture medium supplemented with 10% heat-inactivated FBS, 1 mM sodium pyruvate, 10 mM HEPEs and 0.05 mM β-mercaptoethanol in a humidified atmosphere at 37°C and 5% CO2. Terminal differentiation of THP-1 to macrophages was obtained by rinsing the cells twice with sterile PBS prior to incubation at 37°C with 50 nM PMA for 48 h.

To obtain the PBMC-derived macrophages, human primary monocytes were isolated from heparinized peripheral blood purchased from the Etablissement Français du Sang (EFS) using a Ficol-Paque™ gradient. Blood samples were diluted with an equal volume of PBS and centrifuged at room temperature for 30 min at 400 x g. The EFS authorized the Inserm U1179 research unit (agreement number 15/EFS/012) to use anonymized blood samples for non-therapeutic purposes. PBMCs were cultured in the abovementioned culture medium without β-mercaptoethanol with the addition of 20 ng/ml GM-CSF. A total of 7 days after isolation, non-adherent cells were removed and adherent PBMC-derived macrophages were ready for treatment.

For the BMDMs isolated from Nrf2−/− and Nrf2−/+ littermate mice, bone marrow was extracted from mouse femurs and tibias, washed with PBS and cultured in DMEM supplemented with 20% filtered L929 fibroblast cell line-conditioned media and 10% heat-inactivated FBS in non-treated culture dishes. Conditioned medium was harvested from L929 fibroblasts, grown in DMEM supplemented with 10% heat-inactivated FBS, and 3 days following confluency it was filtered through a 0.22-µm filter and stored at -20°C. A total of 7 days after harvest, all non-adherent cells were removed, and the remaining macrophages were detached by resuspending cells in cold PBS, and by scraping cells after 10 min incubation on ice. BMDMs were stained 1 min at room temperature by diluting the cell suspension with an equal volume of 0.4% trypan blue, counted using the Countess automated cell counter (Thermo Fisher Scientific, Inc.), and seeded in 24-well culture plates at a density of 5x10⁵/well for use the following day.

When required, macrophages were incubated at 37°C with p38 or JNK inhibitors (25 µM SB203580 and 25 µM SP600125, respectively) 1 h prior to addition of 10 µM SFN (23). A total of 3 h after SFN treatment, S. aureus was added at a multiplicity of infection (MOI) of 10, and the cells were incubated at 37°C for an additional 3 h prior to cell lysis and RNA isolation. For 24 h post-infection assays, 20 µg/ml gentamycin was added to cell medium 1 h after S. aureus infection, to eliminate extracellular bacteria.

Total RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR). Total RNA was isolated 3 h after S. aureus infection of macrophages with TRizol® (Invitrogen; Thermo Fisher Scientific, Inc.) and chloroform extraction technique following the manufacturer’s protocol. Total RNA was quantified using the GE NanoVue spectrophotometer (GE Healthcare). To determine mRNA expression levels of target genes HO-1, NQO1, IL-1β, IL-6, TNF-α, C-C motif chemokine receptor 7 (CCR7), IL-23, iNOS, and 8S ribosomal RNA, 1 µg total RNA was reverse transcribed to cDNA using Maxima First strand cDNA synthesis kit following the manufacturer’s protocol. cDNAs were then analyzed by RT-qPCR using iTag SYBR-Green qPCR mix. The thermocycling conditions were as follows: 95°C for 30 sec, followed by 40 cycles of a 5 sec denaturation step at 95°C and a 20 sec annealing/extension step at 60°C. The specific oligonucleotides for human and mouse HO-1, NQO1, IL-1β, IL-6, TNF-α, 18S ribosomal RNA, CCR7, IL-23 and iNOS, listed in Table 1, were synthesized by Eurogentec. Gene expression levels were normalized to that of the reference gene 18S ribosomal RNA. To analyze miRNA expression levels of target genes miR-142-5p and miR-146a-5p, miRNA was reverse transcribed using the miRCURY LNA RT kit. cDNAs were then analyzed by qPCR using miRCURY LNA SYBR PCR kit. miRNA expression levels of target genes were normalized to the internal control U6 snRNA level. RT-qPCR was performed using the CFX96 and CFX384 Touch thermocyclers (Bio-Rad Laboratories, Inc.), with each sample performed in triplicate. Data were analyzed on BioRad CFX manager 3.1 using the 2−ΔΔcq method (24). Each RT-qPCR assay was performed independently and in triplicate.

Bacterial strain, growth culture, and fluorescence labeling of S. aureus. The ATCC 25923TM strain was grown aerobically in Tryptic soy broth to an optical density of 1 at 37°C under agitation. Bacterial glycerol stocks were maintained at -20°C. When required, frozen stocks were thawed and bacteria were diluted to the appropriate inoculum in sterile PBS. For the intracellular bacterial survival assay, bacteria were grown on Tryptic soy broth solidified with 1.5% agar. For the S. aureus internalization assay, fresh fluorescent S. aureus were generated by incubating S. aureus with SYTO9 for 15 min (Thermo Fisher Scientific, Inc.) at room temperature in the dark under gentle shaking, then washing 3 times in sterile PBS, and resuspending in PBS prior to cell infection. S. aureus internalization assay and immunofluorescence labeling. THP-1 cells were seeded in 6-well plates at 1x10⁶ cells/well and differentiated with 50 nM PMA for 48 h. THP-1-derived macrophages were infected with SYTO9-labeled S. aureus at an MOI of 10. After 1 h infection, cells were washed twice with cold PBS to prevent additional bacterial internalization and to remove extracellular bacteria. Cells were then trypsinized at 37°C for 10 min, fixed in 4% paraformaldehyde (PFA) for 15 min at room temperature, and finally suspended in 500 µl 0.02% EDTA. The quantification of cells infected with SYTO9-labeled S. aureus were performed using BD LSRFortessa flow cytometer and analyzed using FACSdiva software 7.0 (BD Biosciences). A forward and side scatter gate was set to exclude dead and aggregated cells. A total of 100,000 events per condition was collected.

For the immunofluorescence labeling, THP-1-derived macrophages seeded at 5x10⁵ cells/coverglass were infected with SYTO9-stained S. aureus for 1 h then cells were rinsed with PBS and fixed for 10 min at room temperature with 4% PFA. Cells were visualized by labeling with phalloidin-ATTO 594.
Table I. Primers used for reverse transcription quantitative polymerase chain reaction analyses.

<table>
<thead>
<tr>
<th>Target gene</th>
<th>Primer sequence (5'-3')</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human CCR7</td>
<td>F GATTACATCGGGACACACAGA</td>
</tr>
<tr>
<td>Human IL-1β</td>
<td>F AATGATGGTTATACAGTGGCA</td>
</tr>
<tr>
<td>Human IL-23</td>
<td>F GTTCCCCATATCCAGTTGG</td>
</tr>
<tr>
<td>Human IL-6</td>
<td>F GTAGCGCCCCACACAGA</td>
</tr>
<tr>
<td>Human TNF-α</td>
<td>F GGAGAAGGGTGACGTCACT</td>
</tr>
<tr>
<td>Mouse HO-1</td>
<td>F CACGCAATATCCGGCTACCT</td>
</tr>
<tr>
<td>Mouse IL-1β</td>
<td>F GCAACTGTTCTGGAATCAACT</td>
</tr>
<tr>
<td>Mouse IL-6</td>
<td>F GTTCCTGGAATACCTGGA</td>
</tr>
<tr>
<td>Mouse iNOS</td>
<td>F TCTTGGAGAAATGGGCGAAG</td>
</tr>
<tr>
<td>Mouse NQO1</td>
<td>F TTTCTTCTCCGATTACAGTAG</td>
</tr>
<tr>
<td>Mouse TNF-α</td>
<td>F TGCTACTCCAGGGTCCTCTT</td>
</tr>
<tr>
<td>Mouse 18S rRNA</td>
<td>F CTGAGAAACGGCTACCCACATC</td>
</tr>
</tbody>
</table>

F, forward; R, reverse; CCR7, C-C motif chemokine receptor 7; IL, interleukin; TNF-α, tumor necrosis factor-α; HO-1, heme oxygenase-1; NQO1, NAD(P)H quinone dehydrogenase 1.

Images were captured using a laser scanning confocal fluorescence microscope (Leica SP8, Leica Microsystems, Inc.) and analyzed using ImageJ v.1.47 software (National Institutes of Health).

**Intracellular survival assay of S. aureus.** For the intracellular bacterial survival assay, macrophages were seeded in 24-well plates at 2.5x10⁵ cells/well and infected with S. aureus at an MOI of 10. After 1 h infection, cells were washed with PBS and extracellular bacteria were eliminated by the addition of 20 µg/ml gentamycin in cell culture medium. After 24 h incubation at 37°C, cells were rinsed with PBS and lysed in 1 ml ice-cold sterile water for 20 min at 4°C. Intracellular bacteria were diluted in 5-fold serial dilutions and then plated on Tryptic soy agar plates. Colony forming units (CFU) counts were determined using the FLUOstar Omega microplate reader (BMG Labtech).

**Caspases-3/7 activity assays.** When indicated, BMDMs seeded in 6-well plates at 1x10⁶ cells/well were pretreated for 3 h with 10 µM SFN or DMSO prior to infection with S. aureus (MOI of 10). Gentamycin 20 µg/ml was added to the culture medium 1 h after infection to eliminate extracellular S. aureus. Staurosporine (1 µM) was used as an apoptosis positive control. Following cell treatment, caspases-3/7 activities were determined using the Green FAM-FLICA Caspases-3/7 assay kit according to the manufacturer's protocol. BMDMs were trypsinized and incubated at 37°C in the dark for 1 h with the FLICA probe, made of the irreversible caspase inhibitor DEVD-fluoromethyl ketone fused to a carboxyfluorescein (FAM-DEVD-FMK), which binds specifically and covalently to activated caspase-3/7 enzymes. Following 2 washes, cells were fixed with 4% PFA for 15 min at room temperature and resuspended in 0.02% EDTA and the number of FLICA-positive cells was counted using the BD LSRFortessa™ flow cytometer and analyzed using FACSdiva 7.0 software (BD Biosciences).

**Protein extraction and western blot analysis.** For total protein extraction, THP-1-derived macrophages were rinsed with cold PBS and then lysed with cold RIPA buffer [150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS and 50 mM Tris-HCl (pH 7.5)], supplemented with protease and phosphatase inhibitor cocktail mixtures. Protein concentrations were determined using the DC protein assay kit. Total proteins (20 µg/lane) were resolved by 4-20% SDS-PAGE and transferred to Immobilon-FL polyvinylidene difluoride membranes (Merck KGaA). Western blot analysis was then performed at room temperature for ~3 h using the iBind Flex Western system (Invitrogen; Thermo Fisher Scientific, Inc) following the manufacturer's protocol. Briefly, primary antibodies against Nrf2 (1:1,000), GAPDH (1:8,000), total and p-ERK (1:2,000 and 1:1,000, respectively), total and p-p38 (1:2,000 and 1:1,000, respectively), total and p-JNK (both 1:1,000), and IRDye680RD- or IRDye800RD-conjugated secondary antibodies (1:4,000 and 1:3,000, respectively) were diluted in iBind Flex FD Solution. Fluorescent blot imaging was performed using Odyssey CLX Imaging system (LI-COR).
Statistical analysis. The data are presented as the mean ± standard error of the mean (SEM) from at least 3 independent experiments. Imaging flow cytometry data are presented as the mean ± SEM of at least 3 independent experiments analyzed from 100,000 events each. Statistical comparisons were performed using two-tailed unpaired t-tests or ANOVA followed by Tukey’s post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

**SFN improves intracellular** *S. aureus* **clearance in macrophages.** In order to gain a better understanding of the effect of SFN on the intracellular fate of *S. aureus* in macrophages, THP-1-derived macrophages were utilized. To visualize the internalization of *S. aureus*, THP-1 monocytes were first differentiated into macrophages with PMA and infected with SYTO9-stained *S. aureus* for 1 h. Following PFA fixation, the macrophages, stained with fluorescent phalloidin and intracellular *S. aureus*, were visualized by confocal microscopy. Analysis of the images of infected macrophages demonstrated the internalization of SYTO9-labeled *S. aureus* in THP-1-derived macrophages, including *S. aureus* enclosed in actin-dependent structures reminding of early phagocytosis (Fig. 1A).

To evaluate the intracellular survival of *S. aureus*, THP-1-derived macrophages were pretreated for 3 h with 10 µM SFN or the vehicle dMSO prior to *S. aureus* infection. A total of 1 h after infection, gentamycin was added to the culture medium to eliminate extracellular bacteria and infected macrophages were incubated for an additional 24 h post-infection. CFU enumeration indicated that intracellular bacteria counts were significantly decreased in SFN pretreated THP-1-derived macrophages compared with the DMSO pretreated cells (Fig. 1B). The inhibitory effect of SFN observed in the THP-1-derived macrophages was confirmed by infecting macrophages derived from human peripheral blood mononuclear cells (PBMCs). PBMCs issued from blood donors and isolated using a Ficoll-Paque™ gradient were first differentiated to macrophages for 7 days with GM-CSF prior to pretreatment with SFN or DMSO and infection with *S. aureus*. SFN pretreated PBMC-derived macrophages exhibited a significant decrease in intracellular bacterial survival 24 h after infection compared to *S. aureus* counts issued from DMSO treated macrophages (Fig. 1C).

Furthermore, to determine whether cytotoxicity contributed to the apparent decrease in bacterial persistence, cell viability was assessed in THP-1-derived macrophages incubated with SFN or infected for 1 h with *S. aureus* prior to the addition of gentamycin and 24 h incubation. The MTT assay revealed that neither SFN nor *S. aureus* affected THP-1-derived macrophage viability as compared with that observed in the DMSO-treated cells (Fig. 1D). Additionally, quantification by flow cytometry of internalized SYTO9-stained *S. aureus* in THP-1-derived macrophages 1 h after infection indicated that SFN pretreatment of macrophages had no effect on *S. aureus* internalization when compared with the DMSO-treated macrophages infected with *S. aureus* (Fig. 1E). The modulation of the oxidative stress by *S. aureus* in THP-1-derived macrophages was also assessed. ROS levels were measured in macrophages 24 h after bacterial challenge in presence of the CellRox fluorogenic probe. Confocal images and fluorescent intensities were analyzed by ImageJ software, and the results indicated that there was no significant modification to ROS production in THP-1-derived macrophages pretreated with SFN and/or infected with *S. aureus* compared with the DMSO-treated macrophages (Fig. S1), indicating that the SFN-mediated inhibition of intracellular *S. aureus* survival in THP-1-derived macrophages was not due to an effect of SFN or *S. aureus* on cell viability or ROS production.

**SFN affects intracellular** *S. aureus* **survival and cell apoptosis in an Nrf2-independent manner.** As SFN is a well-known activator of transcription factor Nrf2, a key regulator of inducible intracellular defenses in the innate immune system, the present study aimed to determine whether SFN activated Nrf2 signaling to impair intracellular survival of *S. aureus* in macrophages. Primary bone marrow stem cells were isolated from Nrf2−/− mice and their control Nrf2+/- littermates, and differentiated into BMDMs using L929-conditioned media. Nrf2−/− and Nrf2+/- BMDMs pretreated with DMSO or SFN were infected with *S. aureus* for 1 h prior to the addition of gentamycin to the culture medium. Total proteins were extracted 24 h after infection and examined by western blot analysis. SFN significantly increased the Nrf2 protein levels in both non-infected and infected Nrf2+/- BMDMs compared with the DMSO-treated macrophages, whereas no detectable Nrf2 was observed in the non-infected and infected macrophages pretreated with DMSO (Fig. 2A). Knockout of Nrf2 in the Nrf2−/- BMDMs was validated by western blot analysis and qPCR analysis of 2 target genes of Nrf2 coding for HO-1 and NQO1. qPCR analysis demonstrated the lack of transcription upregulation of HO-1 and NQO1 in DMSO-treated or *S. aureus*-infected Nrf2+/- BMDM, and in Nrf2−/− BMDMs pretreated with SFN (Fig. 2A-C).

The effect of Nrf2 and Nrf2-knockout on the intracellular survival of *S. aureus* in Nrf2−/- and Nrf2−/− BMDMs pretreated with SFN or DMSO was next investigated. Similar to THP-1-derived macrophages and primary PBMC-derived macrophages (Fig. 1B and C), Nrf2−/- BMDMs exhibited a significant decrease in intracellular bacterial survival when pretreated with SFN compared with Nrf2−/- BMDMs pretreated with DMSO (Fig. 2D). Noticeably, *S. aureus* survival levels were significantly decreased following SFN pretreatment in Nrf2−/- BMDMs, suggesting that the effect of SFN on bacterial survival was independent of Nrf2. Furthermore, bacterial survival was increased in the *S. aureus*-infected Nrf2−/- BMDMs compared with the *S. aureus*-infected Nrf2−/− BMDM, which suggested a role of Nrf2 signaling in moderating intracellular *S. aureus* survival in macrophages, independently of SFN.

Following *S. aureus* infection, immune cells can undergo caspase-dependent cell death to contribute to the control of infection. The resulting apoptotic bodies, comprised of endocytosed pathogens and antigen presenting cell debris, facilitate T-cell response and clearance by neighboring immune cells (25). To verify the effect of SFN on *S. aureus* mediated caspase-3/7 activity, the FAM-FLICA caspase-3/7 assay kit was used on
THP-1-derived macrophages or BMDMs pretreated with SFN or DMSO and infected with \textit{S. aureus}. Gentamycin was added to the medium 1 h after infection and cells were incubated for 24 h post-infection. Apoptosis analysis by flow cytometry indicated that \textit{S. aureus} significantly activated caspases-3/7 in THP-1-derived macrophages and Nrf2\textsuperscript{+/−} BMDMs, while the lack of Nrf2 in \textit{S. aureus}-challenged Nrf2\textsuperscript{−/−} BMDMs resulted in a significant decrease in \textit{S. aureus}-mediated caspase-3/7-dependent cell apoptosis as compared with the DMSO-treated Nrf2\textsuperscript{−/−} BMDMs and \textit{S. aureus}-infected Nrf2\textsuperscript{−/−} BMDMs (Fig. 2E). In addition, an increase in caspases-3/7 activity was detected in the DMSO-treated Nrf2\textsuperscript{−/−} BMDMs as compared with that measured in the DMSO-treated Nrf2\textsuperscript{−/+} BMDM, which was inhibited by SFN pretreatment.

RT-qPCR analyses demonstrated that SFN pretreatment of the THP-1-derived macrophages significantly attenuated the \textit{S. aureus}-mediated increased expression levels of miR-142-5p and miR-146a-5p (Fig. 2F). Altogether, these results suggested a negative correlation between decreased \textit{S. aureus}-mediated cell apoptosis in Nrf2\textsuperscript{−/−} BMDMs and increased intracellular bacterial survival. Although Nrf2 clearly participates in the control of \textit{S. aureus} intracellular persistence, the inhibitory effects of SFN on macrophage bactericidal activity and caspase-dependent cell apoptosis appears to be Nrf2-independent.

SFN inhibits \textit{S. aureus}-induced transcriptional expressions of proinflammatory genes. The inflammatory response triggered by \textit{S. aureus} infection in macrophages and the effect of SFN on \textit{S. aureus}-induced inflammation were then examined. THP-1-derived macrophages were pretreated with SFN or DMSO and infected with \textit{S. aureus}. Total RNAs were extracted 3 h after infection and the transcription levels of the genes coding for proinflammatory cytokines IL-1β, IL-6 and TNF-α...
were measured by RT-qPCR. The levels of IL-1β, IL-6 and TNF-α were significantly increased in the S. aureus-infected THP-1-derived macrophages compared with the non-infected macrophages (Fig. 3A-C). Pretreatment with SFN prior to bacterial challenge prevented S. aureus-mediated increase in IL-1β, IL-6 and TNF-α mRNA expression levels. Similar inhibitory effect of SFN was observed in primary PBMC-derived macrophages infected with S. aureus (Fig. 3D-F).

As Nrf2 has been recently demonstrated to directly affect the transcriptional induction of proinflammatory cytokine genes inflammation in macrophages, the participation of Nrf2 in the regulation of SFN-mediated increase was investigated (19). S. aureus significantly increased the transcriptional expression levels of IL-1β, IL-6 and TNF-α genes in Nrf2+/+ and Nrf2−/− BMDMs, and pretreatment of BMDMs with SFN prevented S. aureus-mediated transcription of the proinflammatory cytokine genes in both macrophages expressing Nrf2 and lacking Nrf2 (Fig. 3G-I), suggesting that SFN inhibited S. aureus-induced inflammation independently of Nrf2.
SFN prevents the S. aureus-induced expression of M1 marker genes in infected macrophages. Upon bacterial infection, activated macrophages produce M1-like proinflammatory marker genes including IL-1β, IL-6 and TNF-α (28). The upregulation of M1 marker genes CCR7 and IL-23 genes in the THP-1-derived macrophages and the INOS gene in the Nrf2-/- BMDMs following S. aureus infection was then confirmed by qPCR (Fig. 4A-C). SFN pretreatment of macrophages attenuated the levels of S. aureus-induced M1 marker genes to those observed in non-infected macrophages. These results suggest that pretreatment with SFN thwarts the classical activation of macrophages by S. aureus.

SFN modulates the MAPK signaling pathway. To investigate the molecular mechanisms employed by SFN to markedly decrease S. aureus-induced inflammation, the present study focused on the MAPK signaling pathways, as MAPK cascades are significantly involved in the macrophage inflammatory responses. ERK, p38 and JNK are the 3 most studied members of the MAPK family. To determine whether S. aureus activated ERK, p38 and JNK, THP-1-derived macrophages were pretreated with DMSO or SFN followed by S. aureus infection. Protein extracts were examined by western blot analysis, and the phosphorylation states of ERK, p38 and JNK were determined. Densitometry analysis of total ERK and phosphorylated ERK protein signals demonstrated a significant increase in phosphorylated ERK in SFN-treated macrophages compared with the DMSO-treated macrophages (Fig. 5A and B). No modification in the activation of the ERK pathway was observed in the S. aureus-challenged macrophages.
macrophages, while phosphorylation of p38 and JNK was significantly augmented (Fig. 5C-F). SFN pretreatment of THP-1-derived macrophages notably prevented activation of p38 and JNK in S. aureus infected and non-infected macrophages. These results suggested a strong inhibitory effect of SFN on the p38 and JNK signaling pathways.

**MAPK-dependent inhibition of IL-1β, IL-6 and TNF-α mRNA expression levels by SFN.** To further investigate whether the anti-inflammatory effect of SFN on the proinflammatory cytokine genes IL-1β, IL-6 and TNF-α resulted from the inhibition of p38 or JNK phosphorylation by SFN, specific p38 and JNK inhibitors were used. THP-1-derived macrophages were pretreated with the p38 inhibitor SB203580 or the JNK inhibitor SP600125 prior to SFN treatment and/or S. aureus infection. qPCR analysis indicated that SB203580 effectively repressed the S. aureus-mediated increase in IL-1β, IL-6 and TNF-α gene expression levels when compared with the DMSO-pretreated macrophages infected with S. aureus (Fig. 6A-C). In addition, the decrease in IL-1β and IL-6 gene expression levels by SB203580 was comparable with that observed in the SFN-pretreated macrophages challenged with S. aureus. SP600125 significantly decreased the expression levels of IL-6 in the THP-1-derived macrophages infected with S. aureus compared with the macrophages pretreated with DMSO and infected with S. aureus (Fig. 7B). Data obtained from the Nrf2+/− BMdMs validated the inhibitory effect of SB203580 on IL-1β and IL-6 gene transcription (Fig. 6D and E), while SP600125 specifically inhibited the transcription of IL-6 and TNF-α genes (Fig. 6E and F).

As SFN suppressed p38 and JNK phosphorylation it was of interest to examine whether pretreatment of macrophages with SB203580 or SP600125 resulted in an attenuation of S. aureus load in macrophages. The THP-1-derived macrophages were pretreated with SFN, SB203580 or SP600125 and challenged with S. aureus for 1 h prior to the addition of gentamycin. CFU counts were determined after 24 h, and a significant decrease in intracellular bacterial survival in macrophages treated with SB203580 or SP600125 was observed, at a level comparable with that obtained in SFN pretreated macrophages (Fig. 6G).

Overall, the results suggested that SFN activation of macrophage bactericidal activity is based on the inhibition of the macrophage proinflammatory responses by inhibiting p38 and JNK MAPK signaling.

Fig. 7 summarizes the hypothesis regarding the role of SFN in inhibiting S. aureus recognition, but not its internalization, thereby preventing p38 and JNK MAPK signaling, and inhibiting MAPK-dependent upregulation of IL-1β, IL-6 and TNF-α proinflammatory cytokine genes, as well as potentially averting macrophage M1 polarization.

**Discussion**

SFN, a naturally-occurring isothiocyanate present in abundance in cruciferous vegetables such as broccoli sprouts, has been demonstrated to possess pleiotropic protective effects against oxidative stress, various types of cancer, inflammatory diseases and microbial infections (11-13). In the present study, the molecular mechanism activated by SFN to improve bacterial clearance in macrophages challenged with S. aureus was identified. It was demonstrated that SFN decreases intracellular bacterial survival by preventing the activation of p38 and JNK signaling pathways activated by S. aureus, 2 major enzymes implicated in the production of inflammatory cytokines. Macrophages treated with SFN exhibited a significant decrease in the levels of S. aureus-induced inflammation, and while the anti-inflammatory activity of SFN has been previously described, the underlying cellular mechanisms involved in this process remains unclear. The use of Nrf2−/− BMdMs also demonstrated that the inhibitory effects of SFN on intracellular bacterial survival and caspase-3/7-dependent apoptosis were Nrf2-independent, but associated with the downregulation of miR-142-5p and miR-146a-5p.

S. aureus is considered a facultative intracellular pathogen, as it has been demonstrated to proliferate extracellularly and intracellularly within various cell types (29). In chronic and recurrent infections, S. aureus may persist several days within the infected macrophages prior to proliferation (30). The present study first validated that the strain of S. aureus used was able to invade and survive within the THP-1-derived macrophages. Upon bacterial recognition by the host innate immune receptors, cascades of highly dynamic signal transduction systems are sequentially activated and amplified, resulting in the proinflammatory response required in the antimicrobial defense mechanism. Therefore, it stands to

![Figure 4](image-url)
reason that bacteria have developed, among their numerous immune evasion strategies, elaborate mechanisms to exploit the host innate immune signal transduction pathways (31). The increase in inflammatory cytokines produced by the inflammatory response in response to bacterial infection has been associated with an increase in the rates of bacterial nosocomial infections (32). Bacteria such as *S. aureus*, *Pseudomonas aeruginosa* and *Acinetobacter* spp., incubated with IL-1β, IL-6 and TNF-α, demonstrated cytokine concentration-dependent growth patterns (32). Bacteria such as *S. aureus, Pseudomonas aeruginosa* and *Acinetobacter* spp., incubated with IL-1β, IL-6 and TNF-α, demonstrated cytokine concentration-dependent growth patterns (32).

A recent study suggested that *S. aureus*-alpha toxin may activate the inflammasome through activation of the acid sphingomyelinase, which resulted in the rapid release of cathepsins and the production of IL-1β and TNF-α in BMDMs (34). The present study demonstrated that *S. aureus* infection of macrophages triggered a robust increase in the transcriptional expression levels of proinflammatory genes, which was associated with increased expression levels of M1 marker genes. The intracellular survival rates of *S. aureus* were observed to benefit from this inflammatory environment.

MAPK signaling pathways are central to the inflammatory response of the innate immune system. In human bronchial epithelial cells, concomitant infection of influenza virus and *S. aureus* synergistically promoted enhanced phosphorylation of p38, ERK and JNK. Treatment of these cells with specific inhibitors of p38 and ERK demonstrated that these signaling pathways...
were associated with the regulation of IL-6 production (35). Herein, the THP-1-derived macrophages and Nrf2+/- BMdMs infected with S. aureus exhibited increased phosphorylation of p38 and JNK MAPK. The rapid inflammatory response was reflected in the marked increase in IL-1β, IL-6, and TNF-α mRNA expression levels in the S. aureus-infected macrophages. IL-1β, IL-6 and TNF-α are proinflammatory cytokines known to initiate and regulate the immune response and inflammation. The use of specific MAPK inhibitors for p38 and JNK signaling allowed a better understanding of the role served by each member of the MAPK family. Based on the results, it was determined that the transcriptional expression levels of the IL-1β, IL-6 and TNF-α genes were p38- and JNK-dependent.

In previous years, a number of compounds have been developed to inhibit protein kinases, with several drugs approved for the treatment of cancer. For treatments of neuroinflammatory disorders, several anti-inflammatory compounds specifically targeting the classical MAPKs, such as p38α MAPK inhibitors, were assessed in clinical trials but were rapidly discontinued as a result of poor safety profiles or low long-term efficacy (36).
Several natural or chemical compounds have also been previously used to modulate the *S. aureus*-mediated inflammatory response by acting on intracellular signal transduction pathways. In a mouse model of *S. aureus*-induced mastitis, mice treated with the natural compound brazilin, present in *Caesalpinia sappan* heartwood, exhibited a decrease in levels of the *S. aureus*-induced inflammatory cytokines IL-1β, IL-6 and TNF-α. SFN decreases inflammation and intracellular bacterial survival in macrophages. SFN decreases cytokine-dependent growth of *S. aureus*, cell inflammation and cell apoptosis in *S. aureus*-infected macrophages by: i) downregulating transcription of genes coding for proinflammatory cytokines by inhibiting phosphorylation of p38 and JNK, and potentially interfering with *S. aureus* recognition by PRR; and ii) downregulating miR-142-5p and miR-146a-5p. SFN, sulforaphane; *S. aureus*, *Staphylococcus aureus*; PRR, pattern-recognition receptors; p38, p38 mitogen-activated protein kinase; JNK, c-Jun N-terminal kinase; IL, interleukin; TNF-α, tumor necrosis factor-α; miR, microRNA.
S. aureus in phagosomes. In addition, using LPS-stimulated RAW264.7 macrophages, Yoon et al (41) demonstrated that SFN suppressed the TLR4-mediated increase in inflammation by hindering TLR4 oligomerization in a thiol-dependent manner. However, alternative pathogen receptors also participated in S. aureus recognition, as TLR2-deficient mice were still able to produce decreased but significant levels of cytokines in response to S. aureus infection (42). Cytosolic receptors such as nucleotide-binding oligomerization domain (NOD)-like receptors, in particular NOD2, participate in intracellular S. aureus recognition (43). Similar to TLR2, NOD2 mediates cytokine responses through activation of the NF-κB and MAPK signaling pathways. Experiments performed on primary epithelial cells isolated from NOD2-deficient mice and TLR2-deficient mice indicated that staphylococcal peptidoglycan co-localized with NOD2 and TLR2. In both mutants, the levels of IL-1β and IL-6 were decreased by one-half compared with the wild-type cells, suggesting the additive effects of each receptor (44). In addition, it is unlikely that SFN disruption of TLR2 oligomerization affects the phagocytosis process of macrophages, as TLR2-deficient macrophages maintain their phagocytic activity (45), which concurs with the similarities in internalized S. aureus levels between DMSO- and SFN-pretreated macrophages observed in the present study. Based on these data, we hypothesize that SFN decreases the recognition of S. aureus with cell wall components by impeding TLR2 heterodimerization, thereby preventing the downstream activation of NF-κB and MAPK signaling pathways, and inhibiting the production of proinflammatory cytokines. Future experiments are required to determine whether SFN interferes with bacterial invasion, intracellular survival, and/or replication, whether the anti-inflammatory and anti-apoptotic molecular mechanisms activated by SFN are effective against methicillin-resistant S. aureus, and whether SFN affects the phagosomal maturation process in bacteria-infected macrophages.

Using BMDMs isolated from the bone marrow of Nrf2-/- and Nrf2+/mice, the present study demonstrated that Nrf2 was necessary in promoting S. aureus-mediated caspases-3/7-dependent cell death. Previously, the anti-inflammatory contribution of Nrf2 was hypothesized to be an indirect effect of the upregulation of genes coding for antioxidant enzymes, with the removal of ROS resulting in a decreased inflammation (46). Herein, as the ROS levels remained unaffected by either S. aureus challenge or SFN stimulation in THP-1-derived macrophages, the contribution of ROS in the regulation of inflammation by SFN was excluded. Despite the marked activation of ERK MAPK and Nrf2 signaling pathways by SFN, the results of the present study clearly established that SFN affects intracellular bacterial survival independently of Nrf2. In contrast with the observations of the present study, several studies have demonstrated that the inhibition of microbial survival in macrophages treated with SFN involved the Nrf2 signaling pathway. In HIV infection, SFN did not interfere with viral entry, but has been demonstrated to inhibit HIV infection in macrophages through Nrf2 activation by preventing viral insertion into host chromosomes (15). In addition, we have previously reported that intracellular survival of Mycobacterium abscessus was decreased through SFN-induced Nrf2-mediated cell apoptosis (23). Recent studies have associated the expression levels of several miRNAs with fundamental cellular processes such as cell apoptosis, phagocytosis, inflammation and macrophage polarization upon bacterial infection (20,47). The present study demonstrated that expression levels of miR-142-5p and miR-146a-5p are negatively regulated by SFN, suggesting their involvement in SFN-mediated decrease of cell apoptosis. miR-146a-5p expression levels are induced by inflammatory stimuli including TNF-α and IL-1β, and exert an anti-inflammatory effect by inhibiting pro-inflammatory genes such as IL-1 receptor associated kinase 1 and TNF receptor associated factor 6 in human adipocytes (48,49). We hypothesize that the lower than expected expression levels of miR-142-5p and miR-146a-5p observed in THP-1-derived macrophages infected by S. aureus may be due to the short incubation time (3 h after infection) in the experiment in the present study. Additional experiments, including increasing the infection time period, or using primary cells such as BMDMs or human PBMCs, will improve the understanding of the effect of SFN-mediated negative regulation of miR-142-5p, miR-146a-5p and other miRNAs on cellular processes such as inflammation, phagocytosis and macrophage polarization, as well as identify their target mRNAs.

In conclusion, this study proposed a more comprehensive view of the molecular mechanism activated by SFN to promote bacteria clearance. Unlike pharmacological compounds that specifically target protein kinases, the present study demonstrated that due to the pleiotropic effects of SFN, SFN may possibly affect a wide range of molecular targets in S. aureus-activated macrophages. The present results suggested that using SFN to regulate the MAPK-inflammatory response pathway and interfere with S. aureus-induced apoptosis may be a promising therapeutic approach to decrease S. aureus intracellular survival.

Acknowledgements

Not applicable.

Funding

This study was supported by the Legs Poix funding from the Chancellerie des Universités de Paris (MB), the National Institute of Health and Medical Research funding (MB and TD), and the University of Versailles-Saint-Quentin-en-Yvelines funding (MB and TD).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

TBD conceived, designed and performed the experiments, analyzed and interpreted data, and wrote the manuscript. SV interpreted data and reviewed the manuscript. MA conceived the study, interpreted data and reviewed the manuscript. All authors read and approved the final manuscript.
Ethics approval and consent to participate

The protocols were approved by the Institutional Animal Ethics Committee CEEA47 PEL VIPHARM of the University of Versailles-Saint-Quentin-en-Yvelines (Montigny-le-Bretonneux, France), and the Ministry of Higher Education, Research and Innovation.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References


This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.